{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014281","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.804707+00:00","generated_at":"2026-05-26T20:57:11.846074+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.","bullets":["David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.","Baker Tilly U.S., LLP ratified as auditor: 18,080,780 for, 7,381 against, 29,477 abstain.","Reverse stock split approved (ratio 1-for-2 to 1-for-15): 16,176,833 for, 1,732,603 against.","2025 Equity Incentive Plan approved: 10,595,402 for, 1,473,888 against, 6,010,237 broker non-votes.","Adjournment authorization approved: 16,811,725 for, 1,270,013 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014281","json":"https://secwatch.observer/filing/0001213900-25-014281.json","markdown":"https://secwatch.observer/filing/0001213900-25-014281.md","text":"https://secwatch.observer/filing/0001213900-25-014281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/0001213900-25-014281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/ea0231253-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T20:57:11.846074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}